Publication | Closed Access

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

Tumor BiologyMedicinePharmacologyInvestigational Drug Mln0128Novel Torc1/2 InhibitorAnti-cancer AgentTumor SuppressorCancer TreatmentOncologyCell BiologyCancer ResearchDrug Discovery